ALT vs. LLY
Compare and contrast key facts about Altimmune, Inc. (ALT) and Eli Lilly and Company (LLY).
Performance
ALT vs. LLY - Performance Comparison
Loading graphics...
ALT vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ALT Altimmune, Inc. | -14.68% | -49.93% | -35.91% | -31.61% | 79.59% | -18.79% | 496.83% | -8.25% | -96.55% | -93.83% |
LLY Eli Lilly and Company | -14.27% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Fundamentals
ALT:
$309.89M
LLY:
$825.96B
ALT:
-$0.97
LLY:
$22.96
ALT:
6.80K
LLY:
12.68
ALT:
1.38
LLY:
31.13
ALT:
$41.00K
LLY:
$65.18B
ALT:
-$14.95M
LLY:
$54.62B
ALT:
-$89.46M
LLY:
$27.94B
Returns By Period
The year-to-date returns for both investments are quite close, with ALT having a -14.68% return and LLY slightly higher at -14.27%. Over the past 10 years, ALT has underperformed LLY with an annualized return of -40.86%, while LLY has yielded a comparatively higher 30.92% annualized return.
ALT
- 1D
- 6.94%
- 1M
- -28.54%
- YTD
- -14.68%
- 6M
- -18.30%
- 1Y
- -38.40%
- 3Y*
- -9.96%
- 5Y*
- -26.13%
- 10Y*
- -40.86%
LLY
- 1D
- 3.74%
- 1M
- -12.57%
- YTD
- -14.27%
- 6M
- 20.93%
- 1Y
- 12.19%
- 3Y*
- 39.90%
- 5Y*
- 39.16%
- 10Y*
- 30.92%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALT vs. LLY — Risk / Return Rank
ALT
LLY
ALT vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Altimmune, Inc. (ALT) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ALT | LLY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.41 | 0.29 | -0.70 |
Sortino ratioReturn per unit of downside risk | 0.05 | 0.69 | -0.63 |
Omega ratioGain probability vs. loss probability | 1.01 | 1.10 | -0.09 |
Calmar ratioReturn relative to maximum drawdown | -0.67 | 0.42 | -1.09 |
Martin ratioReturn relative to average drawdown | -1.02 | 1.02 | -2.05 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| ALT | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.41 | 0.29 | -0.70 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.28 | 1.23 | -1.50 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.29 | 1.04 | -1.33 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.24 | 0.56 | -0.81 |
Correlation
The correlation between ALT and LLY is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
ALT vs. LLY - Dividend Comparison
ALT has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALT Altimmune, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.68% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Drawdowns
ALT vs. LLY - Drawdown Comparison
The maximum ALT drawdown since its inception was -99.94%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for ALT and LLY.
Loading graphics...
Drawdown Indicators
| ALT | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.94% | -68.24% | -31.70% |
Max Drawdown (1Y)Largest decline over 1 year | -62.65% | -30.26% | -32.39% |
Max Drawdown (5Y)Largest decline over 5 years | -90.45% | -34.48% | -55.97% |
Max Drawdown (10Y)Largest decline over 10 years | -99.85% | -34.48% | -65.37% |
Current DrawdownCurrent decline from peak | -99.89% | -17.00% | -82.89% |
Average DrawdownAverage peak-to-trough decline | -80.66% | -19.25% | -61.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.12% | 12.39% | +28.73% |
Volatility
ALT vs. LLY - Volatility Comparison
Altimmune, Inc. (ALT) has a higher volatility of 26.59% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that ALT's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| ALT | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.59% | 9.04% | +17.55% |
Volatility (6M)Calculated over the trailing 6-month period | 58.39% | 26.21% | +32.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 93.96% | 42.44% | +51.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.38% | 32.14% | +62.24% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 142.47% | 29.80% | +112.67% |
Financials
ALT vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Altimmune, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities